"Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on ...

Its breast cancer drug Trastuzumab Deruxtecan (brand name Enhertu), launched in January 2024, emerged as the top-selling new drug brand last year. According to IQVIA data, AstraZeneca had the ...

The results go a long way to firming up sentiment about Enhertu, which had been widely tipped to become a multibillion-dollar brand before the ILD issue dulled some of its lustre. Much of that ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) led the market among new drugs, followed by Sun Pharma, which generated Rs 50 crore from 18 brands, and Dr. Reddy’s, which recorded Rs 45 crore f ...

AZ’s investment comes as the company is seeing strong sales of HER2-targeted ADC Enhertu (trastuzumab deruxtecan ... AZ announced plans to build a brand new $360 million manufacturing ...

The company provides medicines and vaccines in various therapeutic areas, like cardiovascular metabolic, migraine, and women’s health, under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LON:AZN) (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in ...